Korean J Radiol.
2022 Jul;23(7):775-776. 10.3348/kjr.2022.0207.
Response to Letter; Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible, to Our Article; Axillary Adenopathy in Patients with Recent COVID-19 Vaccination: A New Diagnostic Dilemma
- Affiliations
-
- 1Department of Breast Surgery, Sandwell and West Birmingham NHS Trust, City Hospital Birmingham, Birmingham, United Kingdom
- 2Department of Breast Radiology, Sandwell and West Birmingham NHS Trust, City Hospital Birmingham, Birmingham, United Kingdom
- 3Division of Breast Surgery, European Institute of Oncology, IRCCS, Milan, Italy
- 4Division of Breast Radiology, European Institute of Oncology, IRCCS, Milan, Italy
- KMID: 2530753
- DOI: http://doi.org/10.3348/kjr.2022.0207
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible
- Precautions for breast ultrasound examination following COVID-19 vaccination
- COVID-19 Vaccine-Related Axillary and Cervical Lymphadenopathy in Patients with Current or Prior Breast Cancer and Other Malignancies: Cross-Sectional Imaging Findings on MRI, CT, and PET-CT
- Management of Ipsilateral Axillary Lymphadenopathy Detected on Breast Ultrasound after COVID-19 Vaccination
- Anti-SARS-CoV-2 spike antibody response to the third dose of BNT162b2 mRNA COVID-19 vaccine and associated factors in Japanese hemodialysis patients
